Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Target ALS raises $250 million to accelerate ALS research

Target ALS has reached its capital campaign goal of $250 million to accelerate research and fuel scientific breakthroughs in amyotrophic lateral sclerosis (ALS). The campaign was spearheaded by founder Dan Doctoroff, a former deputy New York City mayor who was diagnosed with ALS in late 2021. He was…

Qalsody slows ALS disease progression in real-world settings

Treatment with Qalsody (tofersen) in the real world slowed disease progression in people with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations, a small study reports. It also stabilized patients’ quality of life and lowered levels of nerve damage-related biomarkers, which is consistent with clinical trial data that…

Relyvrio withdrawn from US, Canada after Phase 3 trial results

Relyvrio (sodium phenylbutyrate and taurursodiol), an approved treatment for amyotrophic lateral sclerosis (ALS), was voluntarily removed from the U.S. and Canadian markets. Amylyx Pharmaceuticals, the therapy’s developer, made the decision after top-line results from the Phase 3 PHOENIX trial (NCT05021536) showed that patients who received Relyvrio…

Cigarette smoking tied to greater risk of ALS, especially for women

Cigarette smoking, either currently or in the past, significantly increases the likelihood of developing amyotrophic lateral sclerosis (ALS), particularly for women, according to a pooled meta-analysis of 32 studies. A risk of the neurodegenerative condition was higher in current smokers, and it increased in a non-linear manner with more…

ALS Canada awards $200K to speed global disease research

The ALS Society of Canada (ALS Canada) has awarded two expedited grants totaling $200,000 to international researchers seeking to advance understanding of amyotrophic lateral sclerosis (ALS). Provided through the 2023 ALS Canada Acceleration Grant Program, a $100,000 grant will support Mónica Povedano, MD, at the Hospital de Bellvitge-IDIBELL…